

Cardium Therapeutics, Inc.  
Form SC TO-I/A  
December 16, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Amendment No. 1 to**  
**SCHEDULE TO**  
**TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES**  
**EXCHANGE ACT OF 1934**

**CARDIUM THERAPEUTICS, INC.**

(Name of Subject Company (Issuer) and Filing Persons (Offeror))

Common Stock, Par Value \$0.0001 Per Share

(Title of Class of Securities)

141916 10 6

(CUSIP Number of Class of Securities (Underlying Common Stock))

Dennis M. Mulroy

Chief Financial Officer

Cardium Therapeutics, Inc.

Edgar Filing: Cardium Therapeutics, Inc. - Form SC TO-I/A

12255 El Camino Real, Suite 250

San Diego, California 92130

Telephone: (858) 436-1000

(Name, Address and Telephone Number of Person Authorized to Receive Notices

and Communications on Behalf of Filing Persons)

*Copy to:*

James A. Mercer III, Esq.

Sheppard, Mullin, Richter & Hampton LLP

12275 El Camino Real, Suite 200

San Diego, California 92130

Telephone: (858) 720-7469

**Calculation of Filing Fee**

**Transaction Valuation\***  
\$2,678,000

**Amount of Filing Fee**  
\$190.95

\* Estimated solely for purposes of calculating the amount of the filing fee. Cardium Therapeutics, Inc., is offering certain holders of 10,271,480 of outstanding warrants, the opportunity to exchange such warrants for the shares of common stock of Cardium Therapeutics, Inc., by tendering three warrants in exchange for one share of common stock. The amount of the filing fee assumes that all outstanding warrants will be exchanged and is calculated pursuant to Rule 0-11(b) of the Securities Exchange Act of 1934, as amended, which equals \$71.30 for each \$1,000,000 of the value of the transaction. The transaction value was calculated based on the Black-Scholes Option Pricing Model.

x Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid: \$190.95  
Form or Registration No.: 005-51647

Filing Party:  
Date Filed:

Cardium Therapeutics, Inc.  
December 2, 2010

\*\* Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.  
Check the appropriate boxes below to designate any transactions to which the statement relates:

Edgar Filing: Cardium Therapeutics, Inc. - Form SC TO-1/A

third party tender offer subject to Rule 14d-1.

issuer tender offer subject to Rule 13e-4.

going-private transaction subject to Rule 13e-3.

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

**EXPLANATORY NOTE**

This Amendment No. 1 (this **Amendment No. 1** ) amends and supplements the Tender Offer Statement on Schedule TO (the **Schedule TO** ) filed with the Securities and Exchange Commission on December 2, 2010, relating to an offer by Cardium Therapeutics, Inc., a Delaware corporation, to exchange (the **Warrant Exchange** ) certain outstanding warrants dated March 9, 2007, November 5, 2008 and November 10, 2008 that contain unlimited down round price protection (the **Eligible Warrants** ), on the terms and conditions set forth in the Offer to Exchange dated December 2, 2010, as amended (the **Offer to Exchange** ), filed as Exhibit (a)(1)(A) to the Schedule TO.

This Amendment No. 1 is filed to reflect the amendment of certain terms of the Offer to Exchange by amending only the items of the Schedule TO included below, and unaffected items are not included herein. Except as specifically provided in this Amendment No. 1, the information contained in the Schedule TO remains unchanged. This Amendment No. 1 should be read in conjunction with the Schedule TO. All defined terms used in this Amendment No. 1 have the same meaning as in the Offer to Exchange.

This Amendment and the Schedule TO is intended to satisfy the reporting requirements of Rule 13e-4 under the Securities Exchange Act of 1934, as amended. The information in the Offer to Exchange and the related election form is incorporated by reference as set forth below.

**Items 1, 2, 4, 6, 10 and 11.**

Items 1, 2, 4, 6, 10 and 11 of this Schedule TO are amended and restated as follows:

As permitted by General Instruction F to Schedule TO, information set forth in the Offer to Exchange and the related election form and any supplement or other amendment thereto related to the Warrant Exchange is incorporated by reference in response to Items 1, 2, 4, 6, 10 and 11 of this Schedule TO.

**Item 12. Exhibits.**

The Index to Exhibits attached to this Amendment is incorporated herein by reference.

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Amendment No. 1 to Schedule TO is true, complete and correct.

CARDIUM THERAPEUTICS, INC.

/s/ DENNIS M. MULROY  
**Dennis M. Mulroy**

**Chief Financial Officer**

December 16, 2010

**INDEX TO EXHIBITS**

(a)(1)(A)*	Offer to Exchange Certain Outstanding Warrants for Common Stock.
(a)(1)(B)*	Form of Election Form/Notice of Withdrawal Form/Change of Election Form.
(a)(1)(C)*	Form of Confirmation of Withdrawal Form.
(a)(1)(D)*	Form of Confirmation to holders who elect to participate in the Warrant Exchange program.
(a)(1)(E) <sup>+</sup>	Form of cover letter from Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics, Inc. dated December 2, 2010.
(a)(1)(F)*	Form of cover letter from Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics, Inc.
(b)	Not applicable.
(d)(1) <sup>+</sup>	Form of warrant to purchase common stock issued on March 9, 2007.
(d)(2) <sup>++</sup>	Form of warrant to purchase common stock issued on November 5, 2008 and November 10, 2008.
(g)	Not applicable.
(h)	Not applicable.

\* Filed herewith.

<sup>+</sup> Previously filed.

<sup>++</sup> Incorporated by reference to Exhibit 4.1 to Form 8-K filed March 6, 2007.

<sup>+++</sup> Incorporated by reference to Exhibit 4.2 to Form 8-K filed November 13, 2008.